We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
Read MoreHide Full Article
Key Takeaways
Stryker launched Prophecy for Incompass and Hoffmann LRF smartHEX at the 2026 AOFAS meeting.
Prophecy adds patient-specific planning, 3D visualization and two fixation options for ankle surgery.
smartHEX combines new frame components, mobile patient guidance and updated planning software.
Stryker (SYK - Free Report) recently announced the expansion of its Foot & Ankle portfolio with the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.
Management highlighted that strong customer adoption and positive feedback for Prophecy have encouraged Stryker to expand the platform to the Incompass Total Ankle System. By combining patient-specific surgical planning with its latest total ankle technology, Stryker aims to help surgeons make more informed decisions before surgery. Management also noted AOFAS as an opportunity to showcase the company’s decades of foot and ankle expertise, customer insights and data. The addition of Prophecy Surgical Planning for Incompass and Hoffmann LRF smartHEX further connects planning, implants and reconstruction technologies, providing surgeons with greater flexibility across foot and ankle care.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK stock gained 1.2% at yesterday’s close. Year to date, shares of the company have fallen 18.9% compared with the industry’s 21.2% decline. However, the S&P 500 has risen 10.1% in the same timeframe.
Stryker could see increased demand for its Foot & Ankle offerings by expanding its technology-enabled solutions across total ankle replacement and complex limb reconstruction. Prophecy’s availability with Incompass could support adoption by connecting patient-specific planning with implant selection, while Hoffmann LRF smartHEX broadens the company’s connected limb reconstruction capabilities. Together, the launches may improve cross-selling opportunities, increase surgeon engagement and support portfolio growth across multiple orthopedic procedures.
SYK currently has a market capitalization of $107.98 billion.
Image Source: Zacks Investment Research
More on Prophecy and Hoffmann LRF smartHEX
Prophecy Surgical Planning has supported more than 100,000 ankle cases over the past 14 years. Its integration with the Incompass Total Ankle System provides surgeons with patient-specific surgical planning, enhanced 3D visualization and both resect-through and pin-through fixation options within a connected platform. The Incompass system itself was developed using insights from Prophecy and SOMA, incorporating real-world anatomy and surgical planning into implant design.
Hoffmann LRF smartHEX expands Stryker’s limb reconstruction portfolio with new rings, struts and frame components, along with a mobile application and updated planning software. The platform is designed to support complex deformity correction by connecting patient guidance, surgeon planning and correction capabilities throughout treatment.
Through its mobile application, smartHEX enables patients to stay connected with their surgeon-prescribed correction plan, while the updated planning software and expanded frame options provide greater versatility for limb reconstruction procedures. Together, the two additions reflect Stryker’s efforts to connect digital planning, implants and reconstruction technologies across Foot & Ankle care.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global foot and ankle devices market is estimated to reach $5.8 billion in 2026 and is projected to witness a CAGR of 6.8% through 2035.
Factors such as the rising prevalence of musculoskeletal disorders, increasing incidence of weakened bones and reduced bone density, the increasing number of sports injuries and accidents, surging demand for cosmetic foot surgery and continued advancements in total ankle replacement technologies are supporting market growth.
Other News
Stryker recently announced the successful completion of the first surgical procedure using SportSuite Vision on Apple Vision Pro at Duke Health. FDA-authorized in July, SportSuite Vision is the first application cleared for intraoperative use with Apple Vision Pro. The technology brings digital content, including arthroscopic images, HipCheck, HipMap and CT imaging, into surgeons’ visual fields, reducing reliance on multiple OR monitors and supporting a more streamlined, ergonomic surgical workflow.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
Key Takeaways
Stryker (SYK - Free Report) recently announced the expansion of its Foot & Ankle portfolio with the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.
Management highlighted that strong customer adoption and positive feedback for Prophecy have encouraged Stryker to expand the platform to the Incompass Total Ankle System. By combining patient-specific surgical planning with its latest total ankle technology, Stryker aims to help surgeons make more informed decisions before surgery. Management also noted AOFAS as an opportunity to showcase the company’s decades of foot and ankle expertise, customer insights and data. The addition of Prophecy Surgical Planning for Incompass and Hoffmann LRF smartHEX further connects planning, implants and reconstruction technologies, providing surgeons with greater flexibility across foot and ankle care.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK stock gained 1.2% at yesterday’s close. Year to date, shares of the company have fallen 18.9% compared with the industry’s 21.2% decline. However, the S&P 500 has risen 10.1% in the same timeframe.
Stryker could see increased demand for its Foot & Ankle offerings by expanding its technology-enabled solutions across total ankle replacement and complex limb reconstruction. Prophecy’s availability with Incompass could support adoption by connecting patient-specific planning with implant selection, while Hoffmann LRF smartHEX broadens the company’s connected limb reconstruction capabilities. Together, the launches may improve cross-selling opportunities, increase surgeon engagement and support portfolio growth across multiple orthopedic procedures.
SYK currently has a market capitalization of $107.98 billion.
Image Source: Zacks Investment Research
More on Prophecy and Hoffmann LRF smartHEX
Prophecy Surgical Planning has supported more than 100,000 ankle cases over the past 14 years. Its integration with the Incompass Total Ankle System provides surgeons with patient-specific surgical planning, enhanced 3D visualization and both resect-through and pin-through fixation options within a connected platform. The Incompass system itself was developed using insights from Prophecy and SOMA, incorporating real-world anatomy and surgical planning into implant design.
Hoffmann LRF smartHEX expands Stryker’s limb reconstruction portfolio with new rings, struts and frame components, along with a mobile application and updated planning software. The platform is designed to support complex deformity correction by connecting patient guidance, surgeon planning and correction capabilities throughout treatment.
Through its mobile application, smartHEX enables patients to stay connected with their surgeon-prescribed correction plan, while the updated planning software and expanded frame options provide greater versatility for limb reconstruction procedures. Together, the two additions reflect Stryker’s efforts to connect digital planning, implants and reconstruction technologies across Foot & Ankle care.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global foot and ankle devices market is estimated to reach $5.8 billion in 2026 and is projected to witness a CAGR of 6.8% through 2035.
Factors such as the rising prevalence of musculoskeletal disorders, increasing incidence of weakened bones and reduced bone density, the increasing number of sports injuries and accidents, surging demand for cosmetic foot surgery and continued advancements in total ankle replacement technologies are supporting market growth.
Other News
Stryker recently announced the successful completion of the first surgical procedure using SportSuite Vision on Apple Vision Pro at Duke Health. FDA-authorized in July, SportSuite Vision is the first application cleared for intraoperative use with Apple Vision Pro. The technology brings digital content, including arthroscopic images, HipCheck, HipMap and CT imaging, into surgeons’ visual fields, reducing reliance on multiple OR monitors and supporting a more streamlined, ergonomic surgical workflow.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank & Key Picks
Stryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Inspire Medical Systems (INSP - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.